Interactive/JJ
Visualization/NN
for/IN
Patient-to-Patient/JJ
Comparison/NN
./.
====================
A/DT
visual/JJ
analysis/NN
approach/NN
and/CC
the/DT
developed/VBN
supporting/VBG
technology/NN
provide/VBP
a/DT
comprehensive/JJ
solution/NN
for/IN
analyzing/VBG
large/JJ
and/CC
complex/NN
integrated/VBN
genomic/JJ
and/CC
biomedical/JJ
data/NNS
./.
====================
This/DT
paper/NN
presents/VBZ
a/DT
methodology/NN
that/DT
is/VBZ
implemented/VBN
as/IN
an/DT
interactive/JJ
visual/JJ
analysis/NN
technology/NN
for/IN
extracting/VBG
knowledge/NN
from/IN
complex/NN
genetic/JJ
and/CC
clinical/JJ
data/NNS
and/CC
then/RB
visualizing/VBG
it/PRP
in/IN
a/DT
meaningful/JJ
and/CC
interpretable/JJ
way/NN
./.
====================
By/IN
synergizing/VBG
the/DT
domain/NN
knowledge/NN
into/IN
development/NN
and/CC
analysis/NN
processes/NNS
,/,
we/PRP
have/VBP
developed/VBN
a/DT
comprehensive/JJ
tool/NN
that/DT
supports/VBZ
a/DT
seamless/RB
patient-to-patient/JJ
analysis/NN
,/,
from/IN
an/DT
overview/NN
of/IN
the/DT
patient/NN
population/NN
in/IN
the/DT
similarity/NN
space/NN
to/TO
the/DT
detailed/JJ
views/VBZ
of/IN
genes/NNS
./.
====================
The/DT
system/NN
consists/VBZ
of/IN
multiple/JJ
components/NNS
enabling/VBG
the/DT
complete/JJ
analysis/NN
process/NN
,/,
including/VBG
data/NNS
mining/VBG
,/,
interactive/JJ
visualization/NN
,/,
analytical/JJ
views/VBZ
,/,
and/CC
gene/NN
comparison/NN
./.
====================
We/PRP
demonstrate/VBP
our/PRP$
approach/NN
with/IN
medical/JJ
scientists/NNS
on/IN
a/DT
case/NN
study/NN
of/IN
childhood/NN
cancer/NN
patients/NNS
on/IN
how/WRB
they/PRP
use/VBP
the/DT
tool/NN
to/TO
confirm/VB
existing/VBG
hypotheses/NNS
and/CC
to/TO
discover/RB
new/JJ
scientific/JJ
insights/NNS
./.
====================
Among/IN
cancers/NNS
,/,
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
is/VBZ
the/DT
most/JJS
common/JJ
cancer/NN
occurring/VBG
in/IN
children/NN
and/CC
is/VBZ
the/DT
driving/VBG
paradigm/NN
for/IN
the/DT
work/NN
presented/VBN
in/IN
this/DT
paper/NN
./.
====================
Despite/IN
presenting/VBG
with/IN
similar/JJ
clinical/JJ
features/NNS
,/,
ALL/NN
patients/NNS
do/VBP
not/RB
always/RB
respond/VBP
in/IN
a/DT
similar/JJ
manner/NN
to/TO
the/DT
same/JJ
treatment/NN
strategies/NNS
./.
====================
The/DT
underlying/VBG
complexities/NNS
of/IN
the/DT
disease/NN
are/VBP
not/RB
always/RB
clearly/RB
reflected/VBD
by/IN
the/DT
clinical/JJ
presentation/NN
or/CC
pathological/JJ
results/NNS
./.
====================
Genomic/JJ
variation/NN
,/,
typified/VBN
by/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
,/,
have/VBP
considerable/JJ
influence/VBP
on/IN
how/WRB
humans/NNS
develop/VBP
diseases/NNS
and/CC
respond/VBP
to/TO
pathogens/NNS
,/,
chemicals/NNS
,/,
drugs/NNS
,/,
vaccines/NNS
,/,
and/CC
other/JJ
agents/NNS
[/(
1/CD
]/)
./.
====================
Similarly/RB
,/,
gene/NN
expression/NN
patterns/NNS
in/IN
diagnostic/JJ
bone/NN
marrow/NN
can/MD
predict/VB
the/DT
sub-type/JJ
of/IN
pediatric/JJ
ALL/NN
as/IN
well/RB
as/IN
indicate/VBP
relapse/NN
potential/JJ
[/(
2/CD
,/,
3/CD
]/)
./.
====================
The/DT
co-regulated/JJ
activity/NN
of/IN
genes/NNS
leads/VBZ
to/TO
metabolic/JJ
actions/NNS
that/DT
are/VBP
driven/VBN
by/IN
small/JJ
changes/NNS
in/IN
the/DT
expression/NN
of/IN
a/DT
large/JJ
number/NN
of/IN
genes/NNS
rather/RB
than/IN
large/JJ
changes/NNS
in/IN
only/RB
a/DT
few/JJ
[/(
2/CD
]/)
./.
====================
As/IN
a/DT
result/NN
,/,
understanding/VBG
genomic/JJ
data/NNS
and/CC
biomedical/JJ
data/NNS
(/(
e.g./FW
,/,
annotated/JJ
clinical/JJ
attributes/NNS
,/,
treatment/NN
details/VBZ
,/,
domain/NN
ontologies/NNS
,/,
and/CC
patient/NN
's/POS
background/NN
)/)
is/VBZ
crucial/JJ
to/TO
improving/VBG
the/DT
diagnosis/NN
and/CC
treatment/NN
of/IN
ALL/NN
./.
====================
As/IN
a/DT
rule/JJ
,/,
the/DT
knowledge/NN
discovery/NN
process/NN
involves/VBZ
the/DT
dialog/NN
between/IN
experts/NNS
from/IN
different/JJ
domains/NNS
,/,
including/VBG
laboratory/NN
scientists/NNS
,/,
biostatisticians/NNS
,/,
computational/JJ
biologists/NNS
,/,
and/CC
clinicians/NNS
./.
====================
In/IN
reality/NN
,/,
most/JJS
techniques/NNS
were/VBD
developed/VBN
based/VBN
on/IN
statistical/JJ
analysis/NN
with/IN
simple/JJ
visualization/NN
[/(
4/CD
]/)
in/IN
an/DT
attempt/NN
to/TO
create/VB
techniques/NNS
that/DT
would/MD
be/VB
applicable/JJ
in/IN
several/JJ
domains/NNS
./.
====================
Basic/JJ
statistics/NNS
and/CC
visualizations/NNS
without/IN
effective/JJ
interaction/NN
and/CC
capabilities/NNS
to/TO
control/VB
the/DT
visual/JJ
data/NNS
mining/VBG
process/NN
are/VBP
often/RB
insufficient/JJ
for/IN
the/DT
analysis/NN
and/CC
exploration/NN
processes/NNS
./.
====================
Intelligent/JJ
visualization/NN
of/IN
complex/NN
genomic/JJ
data/NNS
will/MD
therefore/RB
bring/VBG
the/DT
insight/NN
of/IN
information/NN
as/IN
well/RB
as/IN
the/DT
discovery/NN
of/IN
relationships/NNS
,/,
non-trivial/JJ
structures/NNS
,/,
and/CC
irregularities/NNS
that/DT
may/MD
pertain/VB
to/TO
the/DT
disease/NN
course/NN
of/IN
the/DT
patient/NN
./.
====================
Genomic/JJ
datasets/NNS
are/VBP
complex/NN
data/NNS
structures/NNS
with/IN
measurements/NNS
for/IN
millions/NNS
of/IN
SNPs/NNS
affecting/VBG
the/DT
activity/NN
of/IN
several/JJ
thousand/CC
genes/NNS
./.
====================
These/DT
genomic/JJ
'attributes/NNS
'/``
are/VBP
built/JJ
into/IN
models/NNS
that/DT
inform/VBP
us/PRP
about/RB
individual/JJ
patients/NNS
and/CC
allow/VBP
cross-referencing/JJ
and/CC
determining/VBG
the/DT
interconnections/NNS
between/IN
patients/NNS
./.
====================
It/PRP
is/VBZ
important/JJ
then/RB
to/TO
provide/VB
adequate/JJ
tools/NNS
in/IN
order/NN
to/TO
visualize/VB
these/DT
models/NNS
and/CC
interactions/NNS
and/CC
to/TO
simultaneously/RB
examine/VB
many/JJ
attributes/NNS
in/IN
the/DT
context/NN
of/IN
relevant/JJ
clinical/JJ
properties/NNS
that/DT
can/MD
be/VB
measured/VBN
in/IN
real/JJ
time/NN
for/IN
the/DT
purpose/NN
of/IN
assessing/VBG
a/DT
patient/NN
's/POS
clinical/JJ
course/NN
and/CC
directing/VBG
his/DT
clinical/JJ
management/JJ
./.
====================
Fundamentally/RB
,/,
a/DT
large/JJ
number/NN
of/IN
attributes/NNS
need/VBD
to/TO
be/VB
reduced/VBN
to/TO
a/DT
manageable/JJ
size/NN
so/RB
that/IN
data/NNS
visualization/NN
techniques/NNS
can/MD
be/VB
effectively/RB
applied/VBN
./.
====================
Typical/JJ
dimensionality/NN
reduction/NN
methods/NNS
applied/VBN
to/TO
microarray/NN
data/NNS
include/VBP
principle/NN
component/NN
analysis/NN
[/(
5/CD
]/)
,/,
non-negative/JJ
matrix/NN
factorization/NN
[/(
6/CD
]/)
,/,
multidimensional/JJ
scaling/VBG
[/(
7/CD
]/)
,/,
and/CC
local/JJ
linear/JJ
embedding/VBG
[/(
8/CD
]/)
./.
====================
The/DT
choice/NN
of/IN
method/NN
to/TO
apply/RB
depends/VBZ
to/TO
some/DT
extent/NN
on/IN
the/DT
nature/NN
of/IN
the/DT
information/NN
expected/VBN
to/TO
be/VB
encoded/VBN
in/IN
the/DT
dataset/NN
,/,
since/IN
the/DT
quality/NN
of/IN
the/DT
resulting/VBG
reduced/VBD
matrices/NNS
can/MD
vary/VB
across/IN
different/JJ
datasets/NNS
./.
====================
Remarkably/RB
,/,
most/JJS
of/IN
the/DT
visualization/NN
techniques/NNS
use/NN
matrix/NN
heatmaps/RB
,/,
genomic/JJ
coordinates/VBZ
,/,
or/CC
networks/NNS
(/(
or/CC
pathways/NNS
metaphor/NN
)/)
to/TO
represent/VB
multidimensional/JJ
genomic/JJ
data/NNS
[/(
9,10,11/CD
]/)
./.
====================
-/:
Heatmaps/RB
are/VBP
common/JJ
graphical/JJ
representations/NNS
that/DT
are/VBP
used/VBN
to/TO
present/JJ
genomics/NNS
values/NNS
as/IN
matrices/NNS
of/IN
colors/NNS
./.
====================
Matrix/JJ
heatmaps/RB
are/VBP
typically/RB
represented/VBN
as/IN
rectangles/NNS
(/(
such/JJ
as/IN
cBio/JJ
Cancer/NN
Genomics/NNS
Portal/JJ
[/(
12/CD
]/)
and/CC
Caleydo/FW
StratomeX/NN
[/(
13/CD
]/)
)/)
and/CC
occasionally/RB
as/IN
circles/NNS
(/(
such/JJ
as/IN
CircleMap/JJ
[/(
14/CD
]/)
)/)
./.
====================
-/:
Genomic/JJ
Coordinates/NNS
represent/VBP
oncogenomics/NNS
data/NNS
by/IN
showing/VBG
alterations/NNS
tied/VBN
to/TO
their/PRP$
genomic/JJ
loci/NNS
./.
====================
This/DT
approach/NN
is/VBZ
only/RB
suitable/JJ
for/IN
analyzing/VBG
the/DT
genomic/JJ
topography/NN
of/IN
alternations/NNS
or/CC
for/IN
inspecting/VBG
particular/JJ
genomic/JJ
loci/NNS
[/(
9/CD
]/)
./.
====================
Typical/JJ
techniques/NNS
in/IN
this/DT
approach/NN
are/VBP
Genomics/NNS
Viewer/JJR
[/(
15/CD
]/)
,/,
UCSC/NN
Cancer/NN
Denomics/NNS
Browser/NN
[/(
16/CD
]/)
,/,
and/CC
Savant/JJ
Genome/NN
Browser/NN
[/(
17/CD
]/)
./.
====================
-/:
Networks/NNS
(/(
or/CC
graphs/NNS
)/)
can/MD
be/VB
used/VBN
to/TO
show/VB
changes/NNS
in/IN
state/NN
for/IN
1/CD
)/)
interpreting/VBG
and/CC
exploring/VBG
large/JJ
biological/JJ
networks/NNS
and/CC
2/CD
)/)
assembly/RB
and/CC
curation/NN
of/IN
pathways/NNS
(/(
such/JJ
as/IN
Cytoscape/NN
[/(
18/CD
]/)
,/,
VANTED/NN
[/(
19/CD
]/)
,/,
VisANT/NNP
[/(
20/CD
]/)
,/,
NAViGaTOR/NN
[/(
21/CD
]/)
,/,
and/CC
Cerebral/JJ
[/(
22/CD
]/)
)/)
./.
====================
Visualization/NN
techniques/NNS
for/IN
gene/NN
expression/NN
techniques/NNS
that/DT
include/VBP
reasonably/RB
advanced/JJ
visualizations/NNS
are/VBP
presented/VBN
in/IN
[/(
23,24,25/CD
]/)
./.
====================
Other/JJ
good/JJ
visualization/NN
tools/NNS
show/VBP
the/DT
interdependencies/NNS
of/IN
genes/NNS
by/IN
bringing/VBG
gene/NN
expression/NN
into/IN
context/NN
with/IN
pathways/NNS
[/(
26/CD
]/)
or/CC
using/VBG
dimension/NN
reduction/NN
methods/NNS
to/TO
provide/VB
multi-dimensional/JJ
data/NNS
visualizations/NNS
[/(
27/CD
]/)
./.
====================
Web-based/VBN
visual/JJ
analysis/NN
integrates/VBZ
multiple/JJ
visualization/NN
components/NNS
,/,
such/JJ
as/IN
scatterplot/NN
,/,
phylogenetic/JJ
tree/CD
,/,
and/CC
genome-wide/NN
circus/NN
viewer/JJR
,/,
to/TO
enable/VB
the/DT
analysis/NN
[/(
28/CD
]/)
./.
====================
Although/IN
these/DT
tools/NNS
provide/VBP
somewhat/RB
effective/JJ
ways/NNS
for/IN
the/DT
analysis/NN
of/IN
data/NNS
,/,
they/PRP
do/VBP
not/RB
effectively/RB
present/JJ
the/DT
data/NNS
such/JJ
that/IN
medical/JJ
analysts/NNS
can/MD
interactively/RB
explore/VB
and/CC
manipulate/VBP
the/DT
information/NN
./.
====================
Our/PRP$
approach/NN
seeks/VBZ
to/TO
provide/VB
a/DT
capability/NN
for/IN
viewing/VBG
patients/NNS
in/IN
the/DT
similarity/NN
space/NN
based/VBN
on/IN
detailed/JJ
genomic/JJ
and/CC
gene/NN
of/IN
interest/NN
analysis/NN
,/,
representing/VBG
the/DT
underlying/VBG
biological/JJ
basis/NN
for/IN
the/DT
disease/NN
./.
====================
This/DT
paper/NN
presents/VBZ
a/DT
novel/JJ
visual/JJ
analysis/NN
approach/NN
and/CC
a/DT
tool/NN
where/WRB
medical/JJ
scientists/NNS
can/MD
interrogate/VB
large/JJ
and/CC
complex/NN
genomic/JJ
and/CC
biological/JJ
data/NNS
./.
====================
We/PRP
focus/VBP
on/IN
patient-to-patient/JJ
comparisons/NNS
through/IN
the/DT
biological/JJ
data/NNS
,/,
including/VBG
background/NN
and/CC
treatment/NN
,/,
and/CC
high-dimensional/JJ
genomic/JJ
data/NNS
,/,
including/VBG
Affymetrix/JJ
expression/NN
microarrays/NNS
and/CC
Illumina/NN
SNP/NN
microarrays/NNS
./.
====================
The/DT
innovation/JJ
lies/VBZ
in/IN
its/PRP$
capability/NN
of/IN
providing/VBG
seamless/RB
and/CC
multiple/JJ
views/VBZ
of/IN
data/NNS
,/,
from/IN
overview/NN
of/IN
the/DT
entire/JJ
patient/NN
population/NN
with/IN
the/DT
similarity/NN
space/NN
to/TO
overviews/VBZ
,/,
detailed/JJ
views/VBZ
,/,
and/CC
genes/NNS
of/IN
interest/JJ
(/(
GOI/NN
)/)
views/VBZ
of/IN
selected/VBN
items/VBZ
,/,
for/IN
patient-to-patient/JJ
comparison/NN
./.
====================
The/DT
technology/NN
provides/VBZ
various/JJ
ways/NNS
to/TO
display/VB
the/DT
multi-dimensional/JJ
data/NNS
in/IN
cooperation/NN
with/IN
the/DT
automated/JJ
analysis/NN
./.
====================
In/IN
addition/NN
,/,
by/IN
integrating/VBG
domain/NN
knowledge/NN
into/IN
the/DT
development/NN
,/,
we/PRP
have/VBP
provided/VBN
meaningful/JJ
visualization/NN
for/IN
medical/JJ
data/NNS
analysis/NN
as/IN
well/RB
as/IN
a/DT
quality/NN
assurance/NN
tool/NN
to/TO
verify/VB
the/DT
effectiveness/NN
of/IN
the/DT
automated/JJ
analysis/NN
./.
====================
Biological/JJ
background/NN
and/CC
data/NNS
analysis/NN
====================
The/DT
expression/NN
and/CC
genomic/JJ
SNP/NN
profiles/NNS
of/IN
100/CD
pediatric/JJ
B-cell/NN
ALL/NN
patients/NNS
treated/VBN
at/IN
The/DT
Children/NN
's/POS
Hospital/JJ
at/IN
Westmead/JJ
were/VBD
generated/VBN
using/VBG
Affymetrix/JJ
expression/NN
microarrays/NNS
(/(
U133A/NN
,/,
U133A/NN
2.0/CD
,/,
and/CC
U133/NN
Plus/JJ
2.0/CD
)/)
and/CC
Illumina/NN
NS12/NN
SNP/NN
microarrays/NNS
,/,
respectively/RB
./.
====================
Each/DT
Affymetrix/JJ
expression/NN
microarray/NN
has/VBZ
22,277/CD
attributes/NNS
,/,
while/IN
each/DT
Illumina/NN
SNP/NN
microarray/NN
has/VBZ
13,917/CD
attributes/NNS
./.
====================
Each/DT
attribute/VBP
was/VBD
mapped/VBN
to/TO
a/DT
probe/NN
of/IN
DNA/NN
(/(
or/CC
a/DT
gene/NN
)/)
,/,
and/CC
the/DT
value/NN
for/IN
each/DT
attribute/VBP
corresponded/VBD
to/TO
the/DT
expression/NN
levels/NNS
or/CC
genotype/JJ
for/IN
the/DT
gene/NN
(/(
each/DT
DNA/NN
spot/NN
contains/VBZ
picomoles/NNS
(/(
1012/CD
moles/NNS
)/)
of/IN
a/DT
specific/JJ
DNA/NN
sequence/NN
,/,
known/VBN
as/IN
probes/NNS
or/CC
reporters/NNS
)/)
./.
====================
The/DT
annotations/NNS
for/IN
each/DT
gene/NN
were/VBD
mapped/VBN
on/IN
separate/JJ
files/NNS
./.
====================
Expression/NN
microarrays/NNS
were/VBD
hybridized/VBN
with/IN
diagnostic/JJ
bone/NN
marrow/NN
samples/NNS
and/CC
genomic/JJ
microarrays/NNS
were/VBD
hybridized/VBN
with/IN
remission/NN
peripheral/JJ
blood/NN
samples/NNS
./.
====================
The/DT
patients/NNS
were/VBD
treated/VBN
following/VBG
the/DT
Berlin-Frankfurt-Munich/JJ
95/CD
(/(
BFM95/NN
)/)
protocol/NN
or/CC
the/DT
complimentary/JJ
Australian/JJ
and/CC
New/NN
Zealand/NN
Children/NN
's/POS
Hematology/NN
and/CC
Oncology/NN
Group/NN
Study/NN
VIII/NN
(/(
Study/NN
8/CD
)/)
./.
====================
Using/VBG
these/DT
datasets/NNS
,/,
we/PRP
aimed/VBD
to/TO
develop/VB
a/DT
predictive/JJ
model/NN
of/IN
treatment/NN
outcome/NN
by/IN
identifying/VBG
genes/NNS
capable/JJ
of/IN
differentiating/VBG
patients/NNS
that/WDT
survived/VBD
and/CC
those/DT
that/DT
did/VBD
not/RB
./.
====================
To/TO
achieve/VB
this/DT
,/,
we/PRP
applied/VBD
an/DT
attribute/JJ
deletion/NN
approach/NN
:/:
identifying/VBG
and/CC
removing/VBG
genes/NNS
that/WDT
were/VBD
almost/RB
certainly/RB
not/RB
involved/VBN
in/IN
a/DT
biological/JJ
phenomenon/NN
and/CC
patient/NN
comparison/NN
./.
====================
We/PRP
used/VBD
the/DT
attribute/NN
importance/NN
ranking/VBG
that/DT
was/VBD
implemented/VBN
in/IN
'Random/JJ
forest/VBP
'/``
[/(
29/CD
]/)
to/TO
identify/VB
these/DT
genes/NNS
./.
====================
The/DT
remaining/VBG
informative/JJ
genes/NNS
were/VBD
then/RB
used/VBN
to/TO
build/JJ
a/DT
similarity/NN
space/NN
whereby/RB
the/DT
distances/NNS
between/IN
patients/NNS
in/IN
this/DT
space/NN
were/VBD
indicative/JJ
of/IN
genetic/JJ
similarity/NN
./.
====================
The/DT
expression/NN
values/NNS
were/VBD
z-score-normalized/VBN
within/IN
each/DT
platform/NN
,/,
concatenated/VBD
,/,
and/CC
z-score-normalized/VBD
to/TO
minimize/VB
inter-/NN
and/CC
intra-platform/JJ
biases/NNS
./.
====================
For/IN
the/DT
genomic/JJ
SNP/NN
profiles/NNS
,/,
the/DT
theta/NN
scores/VBZ
were/VBD
used/VBN
to/TO
represent/VB
genotypes/NNS
./.
====================
The/DT
two/CD
datasets/NNS
were/VBD
then/RB
concatenated/VBD
,/,
and/CC
30/CD
%/NN
of/IN
all/DT
the/DT
patients/NNS
were/VBD
withheld/IN
from/IN
the/DT
model-building/JJ
process/NN
as/IN
a/DT
validation/NN
set/NN
./.
====================
Eight/CD
bootstraps/RB
of/IN
the/DT
validation/NN
set/NN
's/POS
patients/NNS
were/VBD
generated/VBN
,/,
and/CC
for/IN
each/DT
bootstrap/NN
,/,
a/DT
random/JJ
forest/JJS
was/VBD
performed/VBN
./.
====================
Each/DT
random/JJ
forest/JJS
produced/VBN
an/DT
attribute/NN
ranking/VBG
list/NN
,/,
and/CC
we/PRP
combined/VBD
these/DT
eight/CD
lists/NNS
to/TO
create/VB
a/DT
global/JJ
list/NN
of/IN
an/DT
attribute/NN
's/POS
importance/NN
./.
====================
The/DT
expression/NN
and/CC
SNP/NN
values/NNS
for/IN
the/DT
top/NN
250/CD
genes/NNS
in/IN
this/DT
global/JJ
list/NN
were/VBD
used/VBN
to/TO
create/VB
a/DT
3D/NN
similarity/NN
space/NN
using/VBG
singular/JJ
value/NN
decomposition-a/NN
matrix/NN
decomposition/NN
technique/NN
[/(
30/CD
]/)
./.
====================
The/DT
visual/JJ
analytics/NNS
model/NN
====================
Our/PRP$
visual/JJ
analytics/NNS
model/NN
reflects/VBZ
the/DT
importance/NN
of/IN
the/DT
domain/NN
knowledge/NN
in/IN
the/DT
visual/JJ
analytics/NNS
process/NN
(/(
see/VB
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Earlier/RBR
,/,
we/PRP
mentioned/VBD
the/DT
importance/NN
of/IN
validating/VBG
a/DT
method/NN
by/IN
the/DT
outcomes/NNS
in/IN
the/DT
discipline/JJ
that/DT
the/DT
method/NN
is/VBZ
used/VBN
./.
====================
To/TO
do/VBP
this/DT
,/,
visual/JJ
analytics/NNS
must/MD
adapt/VB
to/TO
the/DT
respective/JJ
discipline/NN
and/CC
conform/VBP
to/TO
the/DT
language/NN
and/CC
norms/NNS
expected/VBN
of/IN
that/DT
discipline/JJ
./.
====================
For/IN
example/NN
,/,
the/DT
expression/NN
of/IN
identified/VBN
significant/JJ
genes/NNS
is/VBZ
required/VBN
to/TO
be/VB
validated/VBN
by/IN
the/DT
domain/NN
experts/VBZ
when/WRB
the/DT
analysis/NN
is/VBZ
undertaken/VBN
in/IN
independent/JJ
laboratories/NNS
./.
====================
An/DT
appropriate/JJ
visualization/NN
helps/VBZ
the/DT
analyst/NN
to/TO
gain/VB
an/DT
understanding/NN
of/IN
the/DT
data/NNS
and/CC
construct/NN
knowledge/NN
through/IN
our/PRP$
powerful/JJ
human/JJ
visual/JJ
perception/NN
and/CC
reasoning/VBG
capabilities/NNS
./.
====================
We/PRP
provide/VBP
three/CD
interactive/JJ
views/VBZ
for/IN
patient-to-patient/JJ
comparison/NN
,/,
including/VBG
1/CD
)/)
overviews/VBZ
of/IN
the/DT
entire/JJ
patient/NN
population/NN
in/IN
the/DT
similarity/NN
space/NN
,/,
2/CD
)/)
detailed/JJ
views/VBZ
of/IN
selected/VBN
patients/NNS
,/,
and/CC
3/CD
)/)
GOI/NN
./.
====================
We/PRP
describe/VBP
these/DT
visualizations/NNS
in/IN
the/DT
following/VBG
sections/NNS
./.
====================
Domain/NN
analysts/NNS
should/MD
be/VB
able/JJ
to/TO
interact/VB
and/CC
explore/VB
through/IN
different/JJ
views/NNS
to/TO
make/VB
further/RBR
discovery/NN
of/IN
,/,
and/CC
insights/NNS
into/IN
,/,
the/DT
data/NNS
./.
====================
They/PRP
can/MD
obtain/VB
a/DT
better/RBR
understanding/NN
of/IN
the/DT
data/NNS
and/CC
their/PRP$
structures/NNS
and/CC
contribute/VBP
their/PRP$
domain/NN
expertise/VBP
to/TO
the/DT
knowledge/NN
discovery/NN
process/NN
./.
====================
From/IN
the/DT
discovery/NN
of/IN
new/JJ
knowledge/NN
,/,
the/DT
analyst/NN
can/MD
evaluate/VB
,/,
refine/VBP
,/,
go/VBP
beyond/JJ
,/,
and/CC
ultimately/RB
confirm/VBP
hypotheses/NNS
built/NN
from/IN
previous/JJ
iterations/NNS
and/CC
automated/JJ
analysis/NN
./.
====================
The/DT
challenge/NN
presented/VBN
to/TO
the/DT
construction/NN
of/IN
appropriate/JJ
visualization/NN
is/VBZ
to/TO
cover/RB
the/DT
range/NN
of/IN
visualizing/VBG
all/DT
of/IN
the/DT
data/NNS
but/CC
making/VBG
only/RB
all/DT
of/IN
the/DT
relevant/JJ
data/NNS
available/JJ
to/TO
the/DT
analyst/NN
when/WRB
it/PRP
is/VBZ
relevant/JJ
to/TO
do/VBP
so/RB
./.
====================
The/DT
presented/VBN
work/NN
was/VBD
developed/VBN
with/IN
strong/JJ
involvement/NN
from/IN
cancer/NN
researchers/NNS
at/IN
the/DT
Children/NN
's/POS
Hospital/JJ
in/IN
Westmead/JJ
,/,
Sydney/NNP
,/,
Australia/NN
,/,
who/WP
are/VBP
experts/VBZ
in/IN
ALL/NN
research/NN
./.
====================
The/DT
philosophy/NN
behind/VBP
the/DT
work/NN
is/VBZ
that/IN
with/IN
this/DT
new/JJ
way/NN
of/IN
looking/VBG
at/IN
genetic/JJ
and/CC
clinical/JJ
details/NNS
from/IN
the/DT
perspectives/NNS
of/IN
both/DT
domain/JJ
knowledge/NN
and/CC
technologies/NNS
,/,
visual/JJ
analytics/NNS
can/MD
provide/VB
a/DT
medium/NN
for/IN
the/DT
discovery/NN
of/IN
genetic/JJ
and/CC
clinical/JJ
problems/NNS
,/,
potentially/RB
leading/VBG
to/TO
improved/JJ
ALL/NN
treatment/NN
strategies/NNS
./.
====================
Interactive/JJ
visualization/NN
====================
The/DT
microarray/NN
automated/JJ
data/NNS
analysis/NN
produced/VBD
a/DT
similarity/NN
space/NN
of/IN
the/DT
patients/NNS
based/VBN
on/IN
their/PRP$
genetic/JJ
properties/NNS
./.
====================
A/DT
mapping/NN
table/JJ
of/IN
250/CD
GOI/NN
is/VBZ
also/RB
created/VBD
during/IN
this/DT
process/NN
./.
====================
In/IN
order/NN
to/TO
present/JJ
these/DT
results/NNS
in/IN
a/DT
form/NN
suitable/JJ
for/IN
visual/JJ
analysis/NN
by/IN
medical/JJ
experts/NNS
,/,
we/PRP
have/VBP
created/VBN
interactive/JJ
visualizations/NNS
that/DT
operate/VBP
with/IN
the/DT
treated/VBN
data/NNS
./.
====================
The/DT
interactive/JJ
visualization/NN
is/VBZ
applied/VBN
to/TO
1/CD
)/)
present/JJ
a/DT
flexible/JJ
,/,
changeable/JJ
,/,
and/CC
meaningful/JJ
display/VBP
of/IN
the/DT
patient/NN
cohort/VBP
;/:
2/CD
)/)
filter/RB
,/,
explore/RB
,/,
and/CC
manipulate/VBP
the/DT
information/NN
;/:
and/CC
3/CD
)/)
interactively/RB
provide/VBP
the/DT
details/NNS
of/IN
both/DT
the/DT
original/JJ
and/CC
processed/VBN
data/NNS
on/IN
demand/CC
./.
====================
Details/NNS
of/IN
the/DT
interactive/JJ
visualization/NN
components/NNS
are/VBP
presented/VBN
as/IN
follows/VBZ
./.
====================
Overview/NN
of/IN
patients/NNS
====================
The/DT
prototype/NN
version/NN
of/IN
the/DT
new/JJ
interactive/JJ
visualization/NN
system/NN
provides/VBZ
the/DT
set/NN
of/IN
views/VBZ
addressing/VBG
the/DT
needs/NNS
described/VBN
above/IN
./.
====================
The/DT
visualization/NN
provides/VBZ
a/DT
global/JJ
overview/NN
of/IN
the/DT
entire/JJ
cohort/NN
structure/NN
and/CC
the/DT
relative/JJ
patient-to-patient/NN
comparisons/NNS
but/CC
then/RB
allows/VBZ
the/DT
analyst/NN
to/TO
drill/VB
into/IN
the/DT
details/NNS
of/IN
the/DT
relationships/NNS
./.
====================
Displaying/VBG
the/DT
entire/JJ
visual/JJ
structure/NN
at/IN
once/RB
allows/VBZ
analysts/NNS
to/TO
move/VB
rapidly/RB
to/TO
any/DT
location/NN
in/IN
the/DT
space/NN
./.
====================
This/DT
makes/VBZ
less/RBR
effort/NN
to/TO
navigate/VB
across/IN
the/DT
large/JJ
structures/NNS
and/CC
explore/VB
specific/JJ
parts/NNS
./.
====================
We/PRP
utilized/VBD
and/CC
extended/VBD
our/PRP$
former/NN
works/NNS
[/(
31/CD
,/,
32/CD
]/)
to/TO
provide/VB
a/DT
flexible/JJ
,/,
simple/JJ
,/,
yet/RB
powerful/JJ
interface/NN
of/IN
the/DT
patient/NN
population/NN
in/IN
the/DT
similarity/NN
space/NN
./.
====================
The/DT
visualization/NN
is/VBZ
capable/JJ
of/IN
displaying/VBG
both/CC
2D/JJ
and/CC
3D/NN
visual/JJ
projections/NNS
of/IN
the/DT
same/JJ
structure/NN
and/CC
switching/NN
between/IN
them/PRP
from/IN
the/DT
same/JJ
``/CD
area/NN
''/CD
in/IN
the/DT
dataset/NN
(/(
see/VB
Figs/NNS
./.
====================
2/CD
and/CC
3/CD
)/)
./.
====================
Although/IN
each/DT
user/NN
might/MD
have/VBP
a/DT
different/JJ
preference/NN
,/,
the/DT
2D/NN
visualization/NN
is/VBZ
normally/RB
a/DT
better/RBR
choice/NN
,/,
thanks/VBZ
to/TO
its/PRP$
simplicity/JJ
and/CC
familiarization/NN
to/TO
the/DT
analyst/NN
,/,
its/PRP$
flexibility/NN
in/IN
interaction/NN
and/CC
attributed/VBD
mapping/VBG
,/,
no/DT
obscuration/NN
,/,
and/CC
perspective/JJ
correction/NN
./.
====================
The/DT
following/VBG
sections/NNS
are/VBP
limited/JJ
to/TO
the/DT
2D/NN
version/NN
that/DT
was/VBD
extended/VBN
from/IN
TabuVis/NN
[/(
31/CD
]/)
./.
====================
It/PRP
is/VBZ
a/DT
robust/JJ
and/CC
powerful/JJ
visual/JJ
analysis/NN
system/NN
that/WDT
provides/VBZ
flexible/JJ
,/,
customizable/JJ
,/,
and/CC
effective/JJ
visualization/NN
for/IN
multidimensional/JJ
data/NNS
./.
====================
Our/PRP$
innovation/JJ
lies/VBZ
in/IN
the/DT
ability/NN
to/TO
provide/VB
an/DT
easy-to-use/JJ
yet/RB
effective/JJ
way/NN
to/TO
view/NN
multidimensional/JJ
data/NNS
at/IN
different/JJ
angles/NNS
by/IN
mapping/VBG
various/JJ
attributes/NNS
to/TO
different/JJ
visual/JJ
properties/NNS
./.
====================
Key/RB
aspects/NNS
for/IN
visually/RB
analyzing/VBG
data/NNS
with/IN
multiple/JJ
attributes/NNS
are/VBP
quality/NN
and/CC
appropriateness/RB
of/IN
the/DT
analytical/JJ
platform/NN
whose/WP$
presentation/NN
can/MD
be/VB
adjusted/VBN
via/IN
domain/NN
experts/VBZ
./.
====================
The/DT
extended/JJ
system/NN
consists/VBZ
of/IN
multiple/JJ
components/NNS
enabling/VBG
the/DT
analysis/NN
process/NN
,/,
including/VBG
data/NNS
processing/NN
,/,
automatic/JJ
marks/NNS
,/,
customizable/JJ
visualization/NN
via/IN
interaction/NN
,/,
control/JJ
attributes/NNS
,/,
filtering/VBG
,/,
statistical/JJ
display/NN
,/,
save/open/JJ
works/NNS
,/,
and/CC
many/JJ
other/JJ
figures/NNS
./.
====================
The/DT
overview/NN
visualization/NN
supports/VBZ
several/JJ
data/NNS
types/NNS
,/,
including/VBG
Integer/NNP
,/,
Float/NN
,/,
Text/JJ
(/(
string/JJ
)/)
,/,
Boolean/JJ
(/(
true/false/RB
,/,
yes/no/RB
,/,
or/CC
0/1/CD
)/)
,/,
Date/NN
(/(
with/IN
various/JJ
format/IN
)/)
,/,
Date/NN
and/CC
Time/JJ
,/,
and/CC
Percentage/NN
./.
====================
The/DT
data/NNS
types/NNS
are/VBP
categorized/VBN
into/IN
two/CD
groups/NNS
:/:
Categorical/JJ
(/(
text/RB
and/CC
boolean/JJ
)/)
and/CC
Quantitative/JJ
(/(
integer/NN
,/,
float/NN
,/,
date/NN
,/,
date/NN
and/CC
time/NN
,/,
and/CC
percentage/NN
)/)
./.
====================
We/PRP
also/RB
map/VBP
each/DT
data/NNS
type/NN
to/TO
a/DT
color/JJ
for/IN
better/RBR
identification/NN
,/,
particularly/RB
text/RB
→/CD
dark/NN
blue/JJ
,/,
boolean/JJ
→/CD
blue/JJ
,/,
integer/NN
→/CD
red/JJ
,/,
float/NN
(/(
and/CC
percentage/NN
)/)
→/CD
orange/RB
,/,
and/CC
date/NN
(/(
and/CC
time/NN
)/)
→/CD
purple/JJ
./.
====================
The/DT
color/JJ
scheme/NN
can/MD
be/VB
easily/RB
modified/VBN
via/IN
a/DT
property/NN
file/JJ
and/or/CC
menus/NN
when/WRB
running/VBG
(/(
see/VB
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Patient/JJ
's/POS
positions/NNS
====================
The/DT
patient/NN
's/POS
positions/NNS
are/VBP
mapped/VBN
into/IN
the/DT
2D/NN
space/NN
according/VBG
to/TO
his/DT
genetic/JJ
property/NN
./.
====================
This/DT
property/NN
reflects/VBZ
the/DT
genetic/JJ
similarity/NN
of/IN
the/DT
patients/NNS
./.
====================
Two/CD
patients/NNS
are/VBP
close/JJ
together/RB
if/IN
their/PRP$
genes/NNS
are/VBP
similar/JJ
,/,
and/CC
conversely/RB
,/,
they/PRP
are/VBP
located/JJ
far/RB
from/IN
each/DT
other/JJ
if/IN
their/PRP$
genetic/JJ
properties/NNS
are/VBP
different/JJ
./.
====================
For/IN
example/NN
,/,
Fig/NN
./.
====================
2/CD
clearly/RB
illustrates/VBZ
two/CD
distinctive/JJ
groups/NNS
of/IN
patients/NNS
,/,
marked/JJ
by/IN
the/DT
dash-line/NN
ovals/NNS
./.
====================
The/DT
small/JJ
group/NN
contains/VBZ
mostly/RB
deceased/VBD
patients/NNS
,/,
while/IN
the/DT
other/JJ
contains/VBZ
patients/NNS
that/WDT
responded/VBD
well/RB
to/TO
the/DT
treatment/NN
and/CC
survived/VBD
the/DT
disease/NN
./.
====================
The/DT
fact/NN
that/IN
the/DT
deceased/VBN
patients/NNS
are/VBP
located/JJ
close/RB
to/TO
each/DT
other/JJ
in/IN
the/DT
gene/NN
space/NN
may/MD
support/VB
the/DT
hypothesis/NN
that/IN
genetic/JJ
properties/NNS
are/VBP
essential/JJ
to/TO
determine/VB
whether/IN
a/DT
patient/NN
is/VBZ
likely/JJ
to/TO
respond/VB
well/RB
in/IN
the/DT
context/NN
of/IN
the/DT
clinical/JJ
treatment/NN
./.
====================
Interactive/JJ
exploration/NN
====================
Mapping/NN
property/NN
====================
Rich/WDT
graphical/JJ
attributes/NNS
are/VBP
employed/VBN
to/TO
provide/VB
clinical/JJ
and/CC
background/NN
properties/NNS
of/IN
the/DT
patients/NNS
./.
====================
The/DT
attributes/NNS
are/VBP
carefully/RB
selected/VBN
based/VBN
on/IN
the/DT
feedback/NN
from/IN
the/DT
medical/JJ
analysts/NNS
./.
====================
The/DT
mapping/NN
property/NN
and/CC
items/VBZ
can/MD
be/VB
easily/RB
adjusted/VBN
,/,
filtered/VBN
(/(
or/CC
hidden/JJ
)/)
,/,
and/or/CC
re-mapped/VBD
to/TO
different/JJ
attributes/NNS
(/(
e.g./FW
,/,
patient/NN
background/NN
and/CC
biomedical/JJ
information/NN
)/)
via/IN
interactive/JJ
menus/JJ
to/TO
suit/VB
the/DT
preferences/NNS
and/CC
new/JJ
requirements/NNS
./.
====================
The/DT
mapping/NN
options/NNS
are/VBP
label/JJ
,/,
axes/NNS
,/,
colors/NNS
,/,
size/NN
,/,
shapes/VBZ
,/,
and/CC
visual/JJ
bars/VBZ
./.
====================
Filtering/VBG
====================
From/IN
the/DT
visualization/NN
,/,
users/VBZ
can/MD
interactively/RB
filter/NN
out/RP
uninteresting/JJ
patients/NNS
to/TO
enhance/VB
the/DT
view/NN
of/IN
the/DT
associated/VBN
data/NNS
./.
====================
Filtering/VBG
can/MD
be/VB
applied/VBN
to/TO
all/DT
categorical/JJ
and/CC
quantitative/JJ
attributes/NNS
through/IN
interactive/JJ
menus/NN
./.
====================
The/DT
filtering/JJ
allows/VBZ
the/DT
researcher/clinician/JJ
(/(
domain/NN
expert/VBP
)/)
to/TO
extract/NN
,/,
picture/NN
,/,
and/CC
interrogate/JJ
specific/JJ
features/NNS
for/IN
the/DT
patients/NNS
selected/VBN
within/IN
the/DT
similarity/NN
space/NN
./.
====================
Fig/NN
./.
====================
4/CD
illustrates/VBZ
the/DT
view/NN
at/IN
a/DT
navigational/JJ
stage/NN
showing/VBG
all/DT
medium-risk/NN
patients/NNS
only/RB
./.
====================
Patient/JJ
identifications/NNS
are/VBP
also/RB
displayed/VBD
in/IN
this/DT
example/NN
./.
====================
The/DT
figure/NN
highlights/VBZ
three/CD
patients/NNS
with/IN
similar/JJ
clinical/JJ
presentations/NNS
,/,
such/JJ
as/IN
they/PRP
were/VBD
all/DT
stratified/JJ
as/IN
medium/NN
risk/NN
(/(
MR/NN
)/)
(/(
blue/JJ
color/JJ
)/)
,/,
but/CC
having/VBG
diverse/JJ
outcomes/NNS
./.
====================
These/DT
patients/NNS
were/VBD
managed/VBN
on/IN
the/DT
two/CD
treatment/NN
protocols/NNS
BFM95/NN
(/(
larger/JJR
size/NN
,/,
ALL48/NN
)/)
and/CC
Study/NN
8/CD
(/(
smaller/JJR
size/NN
,/,
ALL134/NN
and/CC
ALL323/NN
)/)
./.
====================
With/IN
the/DT
patients/NNS
placed/VBN
into/IN
a/DT
similarity/NN
space/NN
based/VBN
on/IN
genetic/JJ
data/NNS
,/,
we/PRP
have/VBP
applied/VBN
further/RBR
computational/JJ
methods/NNS
to/TO
extract/NN
,/,
visualize/VBP
,/,
and/CC
compare/VBP
data/NNS
from/IN
the/DT
chosen/NN
patients/NNS
./.
====================
By/IN
looking/VBG
at/IN
the/DT
figure/NN
,/,
we/PRP
can/MD
quickly/RB
see/VB
that/DT
ALL323/NN
is/VBZ
located/JJ
at/IN
the/DT
top-left/NN
,/,
while/IN
the/DT
other/JJ
two/CD
patients/NNS
are/VBP
positioned/VBN
closely/RB
together/RB
at/IN
a/DT
distance/NN
from/IN
the/DT
first/JJ
patient/NN
./.
====================
This/DT
observation/NN
indicates/VBZ
that/IN
the/DT
two/CD
surviving/VBG
patients/NNS
ALL48/NN
and/CC
ALL134/NN
are/VBP
genetically/RB
similar/JJ
and/CC
that/IN
they/PRP
are/VBP
genetically/RB
different/JJ
from/IN
the/DT
deceased/VBN
patient/NN
,/,
ALL323/NN
./.
====================
Probe/NN
set/NN
analysis/NN
====================
The/DT
system/NN
also/RB
provides/VBZ
a/DT
capability/NN
to/TO
show/VB
and/CC
compare/VBP
the/DT
property/NN
of/IN
a/DT
particular/JJ
probe/NN
set/NN
across/IN
the/DT
patient/NN
's/POS
population/NN
./.
====================
This/DT
property/NN
allows/VBZ
the/DT
analysts/NNS
to/TO
have/VB
a/DT
comparative/JJ
view/NN
of/IN
how/WRB
a/DT
probe/NN
set/NN
in/IN
a/DT
gene/NN
behaves/VBZ
across/IN
the/DT
population/NN
./.
====================
Fig/NN
./.
====================
5/CD
shows/VBZ
an/DT
example/NN
of/IN
the/DT
visualization/NN
of/IN
the/DT
population/NN
that/WDT
is/VBZ
colored/VBN
by/IN
the/DT
value/NN
of/IN
the/DT
probe/NN
set/NN
``/CD
212022_s_at/JJ
''/CD
at/IN
the/DT
gene/NN
``/CD
MKI67/NN
./.
''/CD
====================
The/DT
figure/NN
clearly/RB
indicates/VBZ
the/DT
significant/JJ
difference/NN
of/IN
patients/NNS
in/IN
the/DT
bottom-left/JJ
cluster/NN
,/,
which/WDT
are/VBP
mostly/RB
painted/JJ
with/IN
``/NN
greenish/VBP
''/CD
colors/NNS
,/,
corresponding/VBG
to/TO
the/DT
high/JJ
values/NNS
,/,
in/IN
comparison/NN
to/TO
reddish/VB
colors/NNS
,/,
corresponding/VBG
to/TO
low/JJ
values/NNS
./.
====================
It/PRP
raises/VBZ
a/DT
new/JJ
hypothesis/NN
that/IN
the/DT
probe/NN
set/NN
``/CD
212022_s_at/JJ
''/CD
(/(
or/CC
the/DT
gene/NN
)/)
might/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
specifying/VBG
the/DT
similarity/NN
space/NN
./.
====================
Clustering/NN
====================
We/PRP
provide/VBP
a/DT
clustering/NN
method/NN
to/TO
group/NN
the/DT
patients/NNS
in/IN
the/DT
similarity/NN
space/NN
./.
====================
The/DT
clustering/NN
is/VBZ
used/VBN
to/TO
enhance/VB
the/DT
visibility/NN
of/IN
patients/NNS
in/IN
the/DT
space/NN
as/IN
the/DT
groups/NNS
who/WP
are/VBP
potentially/RB
sharing/VBG
similar/JJ
genomic/JJ
properties/NNS
./.
====================
In/IN
addition/NN
,/,
by/IN
using/VBG
a/DT
filtering/JJ
method/NN
,/,
the/DT
analysts/NNS
can/MD
quickly/RB
filter/NN
out/RP
unwanted/JJ
clusters/NNS
for/IN
clearer/JJ
views/VBZ
of/IN
the/DT
population/NN
./.
====================
We/PRP
applied/VBD
the/DT
k-means++/JJ
clustering/NN
algorithm/NN
[/(
33/CD
]/)
in/IN
the/DT
implementation/NN
./.
====================
The/DT
algorithm/NN
was/VBD
chosen/NN
because/IN
of/IN
its/PRP$
ability/NN
of/IN
choosing/VBG
the/DT
initial/JJ
values/NNS
(/(
or/CC
``/JJ
seeds/VBZ
''/CD
)/)
for/IN
the/DT
popular/JJ
k-means/NNS
clustering/NN
algorithm/NN
and/CC
thus/RB
avoiding/VBG
the/DT
sometimes/RB
poor/JJ
clustering/NN
outcomes/NNS
found/VBN
by/IN
the/DT
standard/JJ
k-means/NNS
algorithm/NN
./.
====================
The/DT
number/NN
of/IN
clusters/NNS
can/MD
be/VB
specified/VBN
via/IN
a/DT
menu/JJ
./.
====================
Fig/NN
./.
====================
6/CD
shows/VBZ
an/DT
example/NN
of/IN
the/DT
visualization/NN
of/IN
the/DT
entire/JJ
patient/NN
population/NN
who/WP
are/VBP
painted/JJ
with/IN
4/CD
colors/NNS
corresponding/VBG
to/TO
4/CD
clusters/NNS
./.
====================
Patient-to-patient/JJ
visual/JJ
analysis/NN
====================
From/IN
the/DT
overview/NN
of/IN
all/DT
patients/NNS
,/,
users/VBZ
can/MD
select/VB
one/CD
or/CC
more/RBR
patients/NNS
as/IN
well/RB
as/IN
groups/NNS
of/IN
patients/NNS
to/TO
analyze/VB
further/JJ
./.
====================
At/IN
first/JJ
glance/NN
,/,
the/DT
analytical/JJ
view/NN
provides/VBZ
full/JJ
information/NN
of/IN
both/DT
genomic/JJ
and/CC
biological/JJ
data/NNS
./.
====================
The/DT
layout/RB
of/IN
the/DT
panels/NNS
is/VBZ
as/IN
follows/VBZ
:/:
1/CD
)/)
the/DT
top-left/NN
panel/NN
displays/VBZ
information/NN
of/IN
the/DT
Affymetrix/JJ
expression/NN
microarrays/NNS
,/,
2/CD
)/)
the/DT
top-right/NN
panel/NN
displays/VBZ
information/NN
of/IN
the/DT
Illumina/NN
SNPs/NNS
,/,
and/CC
3/CD
)/)
the/DT
middle/JJ
table/JJ
displays/VBZ
all/DT
background/JJ
information/NN
of/IN
the/DT
patients/NNS
,/,
and/CC
the/DT
bottom/CC
table/JJ
displays/VBZ
the/DT
treatment/NN
details/VBZ
(/(
see/VB
Fig/NN
./.
====================
7/CD
)/)
./.
====================
Each/DT
probe/NN
set/NN
in/IN
the/DT
gene/NN
is/VBZ
represented/VBN
as/IN
a/DT
point/NN
on/IN
the/DT
x-y/NN
coordinate/VBP
system/NN
./.
====================
All/DT
genes/NNS
are/VBP
distributed/VBN
orderly/RB
from/IN
top/NN
to/TO
bottom/DT
along/IN
the/DT
y-coordinate/NN
while/IN
their/PRP$
values/NNS
are/VBP
represented/VBN
horizontally/RB
at/IN
the/DT
x-coordinate/NN
./.
====================
This/DT
visual/JJ
projection/NN
follows/VBZ
the/DT
biological/JJ
rule-the/DT
order/NN
in/IN
which/WDT
genes/NNS
are/VBP
displayed/VBN
is/VBZ
sorted/VBN
according/VBG
to/TO
chromosomal/JJ
order/NN
./.
====================
A/DT
quick/RB
sort/NN
process/NN
is/VBZ
performed/VBN
in/IN
prior/JJ
to/TO
the/DT
visualization/NN
./.
====================
By/IN
providing/VBG
an/DT
overview/NN
of/IN
the/DT
entire/JJ
genetic/JJ
and/CC
biomedical/JJ
information/NN
,/,
the/DT
analysts/NNS
can/MD
identify/VB
patterns/NNS
and/CC
abnormalities/NNS
before/IN
exploring/VBG
further/RBR
./.
====================
Fig/NN
./.
====================
7/CD
shows/VBZ
an/DT
example/NN
of/IN
the/DT
analytical/JJ
window/NN
of/IN
the/DT
genetic/JJ
and/CC
clinical/JJ
data/NNS
corresponding/VBG
to/TO
patient/NN
ALL323/NN
./.
====================
We/PRP
can/MD
see/VB
that/DT
the/DT
Affymetrix/JJ
expression/NN
microarray/NN
values/NNS
of/IN
this/DT
person/NN
vary/VBP
from/IN
-2/CD
to/TO
4/CD
,/,
in/IN
which/WDT
the/DT
majority/NN
of/IN
the/DT
genes/NNS
'/``
values/NNS
are/VBP
[/(
-1/CD
,/,
0/CD
]/)
./.
====================
It/PRP
is/VBZ
interesting/JJ
to/TO
see/VB
that/DT
there/EX
is/VBZ
a/DT
region/NN
of/IN
loss/NN
of/IN
heterozygosity/NN
in/IN
ALL323/NN
(/(
highlighted/JJ
by/IN
the/DT
red/JJ
dash-line/NN
rectangle/JJ
)/)
./.
====================
Following/VBG
our/PRP$
revised/VBD
model/NN
of/IN
the/DT
visual/JJ
analytics/NNS
process/NN
,/,
the/DT
analytical/JJ
exploration/NN
is/VBZ
an/DT
essential/JJ
process/NN
to/TO
discover/JJ
insight/NN
and/CC
knowledge/NN
./.
====================
We/PRP
provide/VBP
a/DT
variety/NN
of/IN
functions/NNS
to/TO
support/VB
the/DT
visual/JJ
exploration/NN
and/CC
analysis/NN
,/,
including/VBG
highlighting/JJ
the/DT
importance/NN
or/CC
difference/NN
,/,
zooming/VBG
,/,
filtering/VBG
,/,
detailing/VBG
on/IN
demand/CC
,/,
and/CC
comparing/VBG
multiple/JJ
patients/NNS
or/CC
groups/NNS
of/IN
patients/NNS
./.
====================
A/DT
user/NN
can/MD
interactively/RB
highlight/VBP
GOI/NN
and/CC
significantly/RB
different/JJ
genes/NNS
as/IN
well/RB
as/IN
deemphasize/VBP
the/DT
others/NNS
./.
====================
This/DT
feature/NN
allows/VBZ
one/CD
to/TO
gain/VB
a/DT
better/RBR
view/NN
of/IN
those/DT
GOI/NN
in/IN
comparison/NN
with/IN
the/DT
entire/JJ
gene/NN
structure/NN
./.
====================
The/DT
user/NN
can/MD
also/RB
select/JJ
the/DT
option/NN
of/IN
displaying/VBG
those/DT
GOI/NN
only/RB
./.
====================
A/DT
semantic/JJ
zooming/VBG
technique/NN
is/VBZ
applied/VBN
to/TO
zoom/VB
in/IN
(/(
or/CC
zoom/IN
out/RP
)/)
on/IN
any/DT
particular/JJ
area/NN
of/IN
focus/NN
(/(
see/VB
Fig/NN
./.
====================
8/CD
)/)
,/,
which/WDT
allows/VBZ
the/DT
analyst/NN
to/TO
explore/VB
and/CC
view/NN
in/IN
detail/NN
the/DT
genetic/JJ
information/NN
./.
====================
The/DT
level/NN
of/IN
details/NNS
is/VBZ
updated/VBN
dynamically/RB
depending/VBG
on/IN
the/DT
amount/NN
of/IN
focused/VBN
genes/NNS
and/CC
the/DT
size/NN
of/IN
the/DT
windows/NNS
./.
====================
This/DT
property/NN
ensures/VBZ
the/DT
best/JJS
fit/NN
of/IN
information/NN
on/IN
the/DT
available/JJ
space/NN
./.
====================
In/IN
addition/NN
,/,
detailed/JJ
information/NN
of/IN
a/DT
particular/JJ
gene/NN
is/VBZ
shown/VBN
when/WRB
the/DT
mouse/NN
is/VBZ
over/IN
the/DT
gene/NN
(/(
see/VB
Fig/NN
./.
====================
8E/CD
and/CC
8F/NN
)/)
./.
====================
Fig/NN
./.
====================
8/CD
shows/VBZ
an/DT
example/NN
of/IN
the/DT
visualization/NN
of/IN
patient/NN
ALL323/NN
(/(
same/JJ
as/IN
Fig/NN
./.
====================
7/CD
)/)
when/WRB
various/JJ
options/NNS
and/CC
navigations/NNS
are/VBP
applied/VBN
./.
====================
In/IN
particular/JJ
,/,
the/DT
figure/NN
presents/VBZ
the/DT
views/FW
when/WRB
a/DT
)/)
the/DT
GOI/NN
are/VBP
emphasized/VBN
from/IN
the/DT
structure/NN
,/,
b/LS
)/)
the/DT
view/NN
shows/VBZ
the/DT
GOI/NN
only/RB
,/,
c/NNP
)/)
the/DT
significantly/RB
different/JJ
genes/NNS
are/VBP
highlighted/JJ
,/,
d/IN
)/)
the/DT
significantly/RB
different/JJ
genes/NNS
are/VBP
highlighted/JJ
within/IN
the/DT
GOI/NN
,/,
e/NN
)/)
zoom/IN
in/IN
is/VBZ
applied/VBN
to/TO
SNP/NN
data/NNS
(/(
at/IN
the/DT
right/JJ
panel/NN
)/)
,/,
and/CC
f/IN
)/)
the/DT
user/NN
zooms/NNS
in/IN
on/IN
the/DT
gene/NN
expression/NN
data/NNS
(/(
at/IN
the/DT
left/JJ
panel/NN
)/)
so/RB
that/IN
the/DT
detailed/JJ
information/NN
of/IN
probe/NN
sets/NNS
in/IN
the/DT
genes/NNS
is/VBZ
displayed/VBN
./.
====================
We/PRP
also/RB
provide/VBP
a/DT
mechanism/NN
to/TO
compare/VB
multiple/JJ
patients/NNS
by/IN
aligning/VBG
the/DT
analytical/JJ
windows/VBZ
together/RB
./.
====================
This/DT
figure/NN
is/VBZ
particularly/RB
helpful/JJ
for/IN
identifying/VBG
the/DT
similarities/NNS
,/,
differences/NNS
,/,
regularities/VBZ
,/,
and/CC
irregularities/NNS
of/IN
the/DT
patients/NNS
./.
====================
Fig/NN
./.
====================
9/CD
presents/VBZ
the/DT
view/NN
of/IN
genetic/JJ
and/CC
clinical/JJ
information/NN
of/IN
the/DT
3/CD
chosen/NN
patients/NNS
(/(
highlighted/JJ
in/IN
Fig/NN
./.
====================
4/CD
)/)
./.
====================
First/RB
,/,
the/DT
complete/JJ
data/NNS
of/IN
each/DT
patient/NN
can/MD
be/VB
directly/RB
compared/VBN
./.
====================
By/IN
way/NN
of/IN
example/JJ
,/,
the/DT
figure/NN
indicates/VBZ
a/DT
significant/JJ
difference/NN
of/IN
patient/NN
ALL323/NN
when/WRB
compared/VBN
to/TO
the/DT
other/JJ
two/CD
patients/NNS
ALL48/NN
and/CC
ALL134-in/JJ
particular/JJ
,/,
a/DT
region/NN
of/IN
loss/NN
of/IN
heterozygosity/NN
in/IN
ALL323/NN
,/,
a/DT
region/NN
that/IN
may/MD
contain/VB
the/DT
genetic/JJ
differences/NNS
with/IN
ALL134/NN
and/CC
ALL48/NN
,/,
which/WDT
may/MD
explain/VB
the/DT
differences/NNS
in/IN
treatment/NN
outcome/RB
despite/IN
being/VBG
considered/VBN
similar/JJ
according/VBG
to/TO
the/DT
clinical/JJ
presentation/NN
./.
====================
We/PRP
now/RB
describe/VBP
the/DT
technical/JJ
details/VBZ
for/IN
visualization/NN
of/IN
the/DT
complete/JJ
set/NN
of/IN
SNPs/NNS
and/CC
probe/NN
sets/NNS
for/IN
the/DT
genes/NNS
represented/VBN
by/IN
the/DT
250/CD
developed/VBD
features/NNS
./.
====================
Visual/JJ
analysis/NN
of/IN
GOI/NN
====================
The/DT
traditional/JJ
methods/NNS
usually/RB
use/NN
heatmaps/RB
to/TO
show/VB
all/DT
probe/NN
sets/NNS
or/CC
genes/NNS
in/IN
the/DT
datasets/NNS
./.
====================
Although/IN
this/DT
approach/NN
can/MD
show/VB
the/DT
overview/NN
,/,
its/PRP$
visualizations/NNS
are/VBP
very/RB
dense/JJ
./.
====================
It/PRP
makes/VBZ
it/PRP
really/RB
difficult/JJ
to/TO
analyze/VB
those/DT
important/JJ
genes/NNS
in/IN
detail/NN
from/IN
the/DT
crowded/JJ
population/NN
./.
====================
Our/PRP$
system/NN
innovatively/RB
focuses/VBZ
the/DT
interactive/JJ
visualization/NN
of/IN
the/DT
GOI/NN
resulting/VBG
from/IN
the/DT
automated/JJ
analysis/NN
./.
====================
By/IN
reducing/VBG
the/DT
overhead/JJ
of/IN
analyzing/VBG
a/DT
large/JJ
quantity/NN
of/IN
genes/NNS
,/,
the/DT
analysts/NNS
can/MD
easily/RB
compare/VBP
the/DT
GOI/NN
through/IN
a/DT
large/JJ
population/NN
of/IN
patients/NNS
./.
====================
The/DT
Gene/NN
Comparison/NN
Interactive/JJ
Visualization/NN
is/VBZ
designed/VBN
to/TO
allow/VB
an/DT
analyst/NN
to/TO
drill/VB
down/RB
further/RBR
into/IN
the/DT
genetics/NNS
and/CC
treatment/NN
data/NNS
of/IN
patients/NNS
identified/VBD
as/IN
significant/JJ
by/IN
the/DT
processes/NNS
described/VBN
in/IN
the/DT
previous/JJ
sections/NNS
./.
====================
This/DT
visualization/NN
implements/NNS
several/JJ
mechanisms/NNS
whereby/RB
the/DT
similarity/NN
and/CC
differences/NNS
between/IN
patients/NNS
and/CC
groups/NNS
of/IN
patients/NNS
can/MD
be/VB
examined/VBN
in/IN
greater/JJR
detail/NN
./.
====================
An/DT
important/JJ
feature/NN
of/IN
this/DT
interactive/JJ
visualization/NN
is/VBZ
the/DT
use/NN
of/IN
active/JJ
regions/NNS
to/TO
indicate/VB
what/IN
the/DT
analyst/NN
is/VBZ
currently/RB
focused/VBN
on/IN
./.
====================
Knowing/VBG
this/DT
makes/VBZ
it/PRP
possible/JJ
to/TO
infer/VB
what/WP
extra/JJ
information/NN
the/DT
analyst/NN
might/MD
find/VB
useful/JJ
and/CC
to/TO
make/VB
sure/NN
that/DT
it/PRP
is/VBZ
available/JJ
./.
====================
This/DT
interactive/JJ
visualization/NN
consists/VBZ
of/IN
5/CD
separate/JJ
visual/JJ
components/NNS
:/:
A/DT
)/)
the/DT
primary/JJ
patient/NN
probe/NN
set/NN
heatmap/RB
component/NN
,/,
B/NN
)/)
the/DT
gene/NN
zoom/IN
component/NN
,/,
C/NN
)/)
the/DT
color/JJ
gradient/JJ
and/CC
Gaussian/JJ
curve/JJ
component/NN
,/,
D/NN
)/)
the/DT
gene/NN
ontology/RB
and/CC
probe/NN
set/NN
annotation/NN
component/NN
,/,
and/CC
E/NN
)/)
the/DT
patient/NN
biomedical/JJ
data/NNS
component/NN
(/(
see/VB
Fig/NN
./.
====================
10/CD
)/)
./.
====================
These/DT
5/CD
components/NNS
are/VBP
designed/VBN
to/TO
interact/VB
with/IN
each/DT
other/JJ
as/IN
well/RB
as/IN
other/JJ
components/NNS
,/,
including/VBG
the/DT
``/NN
Patient-to-Patient/JJ
Visual/JJ
Analysis/NN
''/RB
(/(
described/VBN
in/IN
section/NN
6/CD
)/)
and/CC
the/DT
main/JJ
visualization/NN
(/(
described/VBN
in/IN
section/NN
5/CD
)/)
in/IN
several/JJ
different/JJ
ways/NNS
to/TO
assist/VB
the/DT
analyst/JJ
to/TO
examine/VB
the/DT
similarities/NNS
and/CC
differences/NNS
between/IN
significant/JJ
patients/NNS
and/CC
significant/JJ
groups/NNS
of/IN
patients/NNS
./.
====================
Fig/NN
./.
====================
11/CD
presents/VBZ
an/DT
overview/NN
of/IN
the/DT
visualization/NN
of/IN
the/DT
entire/JJ
Genes/NNS
of/IN
Interest/JJ
Visual/JJ
Analysis/NN
module/NN
when/WRB
the/DT
3/CD
patients/NNS
highlighted/VBD
in/IN
the/DT
similarity/NN
space/NN
are/VBP
added/VBN
./.
====================
Please/NN
note/NN
that/IN
the/DT
figure/NN
shows/VBZ
both/CC
the/DT
probe/NN
set/NN
heatmap/NN
component/NN
and/CC
the/DT
patient/NN
information/NN
component/NN
./.
====================
The/DT
prototype/NN
has/VBZ
been/VBN
used/VBN
for/IN
analyzing/VBG
the/DT
biomedical/JJ
and/CC
genomic/JJ
datasets/NNS
of/IN
100/CD
ALL/NN
cancer/NN
patients/NNS
,/,
from/IN
the/DT
perspectives/NNS
of/IN
domain/NN
knowledge/NN
and/CC
technologies/NNS
./.
====================
In/IN
spite/NN
of/IN
the/DT
size/NN
limitation/NN
of/IN
the/DT
dataset/NN
due/JJ
to/TO
the/DT
expensive/JJ
data/NNS
collection/NN
,/,
the/DT
discovery/NN
is/VBZ
quite/RB
encouraging/VBG
in/IN
the/DT
case/NN
of/IN
ALL/NN
patients/NNS
./.
====================
This/DT
pilot/NN
result/NN
will/MD
place/VB
a/DT
foundation/JJ
,/,
enabling/VBG
further/RBR
enhancement/NN
and/CC
discovery/NN
using/VBG
more/RBR
comprehensive/JJ
datasets/NNS
and/or/CC
clinical/JJ
trials/NNS
./.
====================
On/IN
the/DT
basis/NN
that/IN
patients/NNS
who/WP
cluster/NN
together/RB
will/MD
have/VBP
genotypically/RB
similar/JJ
tumors/NNS
,/,
it/PRP
is/VBZ
then/RB
anticipated/JJ
that/DT
newly/RB
diagnosed/VBN
and/CC
as/IN
yet/RB
untreated/JJ
patients/NNS
will/MD
be/VB
compared/VBN
directly/RB
to/TO
local/JJ
'biologically/RB
'/``
similar/JJ
neighbors/NNS
./.
====================
By/IN
comparing/VBG
the/DT
management/JJ
and/CC
treatment/NN
outcomes/NNS
for/IN
patients/NNS
in/IN
this/DT
manner/NN
,/,
the/DT
analyst/NN
(/(
i.e./FW
,/,
clinician/JJ
)/)
can/MD
glean/JJ
specific/JJ
information/NN
from/IN
the/DT
local/JJ
neighbors/NNS
that/DT
will/MD
assist/VB
with/IN
their/PRP$
clinical/JJ
decision/NN
making/VBG
for/IN
the/DT
individual/JJ
patient/NN
,/,
moving/VBG
towards/IN
the/DT
'personalization/NN
'/``
of/IN
medicine/JJ
./.
====================
The/DT
analysis/NN
has/VBZ
partially/RB
confirmed/VBD
this/DT
accuracy/NN
of/IN
the/DT
similarity/NN
space/NN
./.
====================
To/TO
illustrate/VB
this/DT
,/,
Fig/NN
./.
====================
11A/CD
highlights/VBZ
three/CD
patients/NNS
with/IN
the/DT
red-dash/JJ
ellipses/NNS
,/,
where/WRB
the/DT
deceased/VBN
patient/NN
ALL123/NN
is/VBZ
at/IN
the/DT
top/NN
left/NN
and/CC
the/DT
surviving/VBG
patients/NNS
ALL26/NN
and/CC
ALL302/NN
are/VBP
located/JJ
close/RB
to/TO
each/DT
other/JJ
at/IN
the/DT
near-bottom/JJ
right/JJ
./.
====================
These/DT
patients/NNS
have/VBP
similar/JJ
clinical/JJ
presentations/NNS
,/,
such/JJ
as/IN
all/DT
being/VBG
stratified/VBN
as/IN
high-risk/JJ
,/,
but/CC
diverse/JJ
outcomes/NNS
./.
====================
Fig/NN
./.
====================
11B/NN
shows/VBZ
the/DT
detailed/JJ
views/VBZ
of/IN
the/DT
biomedical/JJ
and/CC
genomic/JJ
data/NNS
of/IN
the/DT
three/CD
selected/VBN
patients/NNS
,/,
showing/VBG
the/DT
significant/JJ
difference/NN
in/IN
gene/NN
expression/NN
values/NNS
of/IN
patient/NN
ALL123/NN
in/IN
comparison/NN
with/IN
ALL26/NN
and/CC
ALL302/NN
./.
====================
This/DT
property/NN
may/MD
explain/VB
the/DT
differences/NNS
in/IN
treatment/NN
outcome/NN
of/IN
the/DT
three/CD
patients/NNS
despite/IN
the/DT
similar/JJ
clinical/JJ
presentation/NN
and/CC
treatment/NN
regimen/NNS
./.
====================
The/DT
interactive/JJ
heatmap/NN
visualization/NN
of/IN
the/DT
expanded/VBN
set/NN
of/IN
SNPs/NNS
and/CC
gene/NN
expression/NN
probe/NN
sets/NNS
used/VBN
in/IN
the/DT
array/NN
platforms/NNS
allows/VBZ
the/DT
analyst/NN
to/TO
examine/VB
each/DT
specific/JJ
genetic/JJ
attribute/VBP
represented/VBN
by/IN
the/DT
250/CD
features/NNS
(/(
Fig/NN
./.
====================
11C/NN
)/)
that/WDT
further/JJ
confirm/VB
the/DT
hypothesis/NN
./.
====================
We/PRP
also/RB
carried/VBD
out/RP
an/DT
analysis/NN
for/IN
different/JJ
groups/NNS
of/IN
patients/NNS
./.
====================
The/DT
experiments/NNS
also/RB
confirm/VBP
the/DT
effectiveness/NN
of/IN
the/DT
similarity/NN
space/NN
./.
====================
For/IN
example/NN
,/,
the/DT
genetic/JJ
analysis/NN
of/IN
four/CD
clusters/NNS
of/IN
patients/NNS
(/(
see/VB
Fig/NN
./.
====================
5/CD
)/)
has/VBZ
unveiled/JJ
that/DT
all/DT
probe/NN
sets/NNS
of/IN
the/DT
gene/NN
MKI67/NN
of/IN
the/DT
patients/NNS
in/IN
cluster/NN
0/CD
(/(
at/IN
the/DT
bottom-left/JJ
and/CC
painted/JJ
with/IN
a/DT
light-pink/NN
color/JJ
)/)
are/VBP
significantly/RB
different/JJ
from/IN
the/DT
others/NNS
(/(
see/VB
Fig/NN
./.
====================
12/CD
)/)
./.
====================
Further/RB
visualization/NN
with/IN
the/DT
probe/NN
set/NN
mapping/VBG
across/IN
the/DT
patient/NN
's/POS
population/NN
has/VBZ
confirmed/VBN
this/DT
property/NN
(/(
see/VB
Fig/NN
./.
====================
5/CD
)/)
./.
====================
Details/NNS
of/IN
the/DT
other/JJ
findings/NNS
(/(
and/CC
the/DT
confirmation/NN
of/IN
the/DT
prognoses/NNS
)/)
are/VBP
described/VBN
further/RBR
as/IN
follows/VBZ
./.
====================
There/EX
is/VBZ
little/JJ
coherence/NN
between/IN
the/DT
genomic/JJ
property/NN
and/CC
the/DT
biomedical/JJ
property/NN
,/,
such/JJ
as/IN
risk/NN
,/,
dead/JJ
,/,
or/CC
survival/NN
rate/NN
./.
====================
Similar/JJ
patients/NNS
in/IN
terms/NNS
of/IN
background/NN
and/CC
clinical/JJ
information/NN
might/MD
have/VB
significant/JJ
differences/NNS
in/IN
their/PRP$
genetic/JJ
properties/NNS
./.
====================
For/IN
example/NN
,/,
Fig/NN
./.
====================
13/CD
illustrates/VBZ
the/DT
details/NNS
of/IN
several/JJ
genes/NNS
of/IN
interest/NN
for/IN
the/DT
four/CD
patients/NNS
:/:
ALL92/NN
,/,
ALL129/NN
,/,
ALL323/NN
,/,
and/CC
ALL321/NN
./.
====================
The/DT
patients/NNS
'/``
clinical/JJ
properties/NNS
are/VBP
similar/JJ
,/,
including/VBG
MR/NN
,/,
male/JJ
,/,
deceased/VBD
,/,
and/CC
Study/NN
8/CD
protocol/NN
./.
====================
However/RB
,/,
the/DT
Affymetrix/JJ
expression/NN
microarrays/NNS
and/CC
Illumina/NN
SNPs/NNS
values/NNS
are/VBP
quite/RB
varied/VBN
among/IN
these/DT
patients/NNS
./.
====================
Early/JJ
treatments/NNS
are/VBP
more/RBR
effective/JJ
than/IN
late/JJ
treatments/NNS
(/(
see/VB
Fig/NN
./.
====================
14/CD
)/)
./.
====================
Particularly/RB
,/,
there/EX
was/VBD
only/RB
one/CD
death/NN
out/IN
of/IN
19/CD
cases/NNS
(/(
95/CD
%/NN
chance/NN
of/IN
survival/NN
from/IN
the/DT
disease/NN
)/)
if/IN
the/DT
treatment/NN
was/VBD
started/VBN
within/IN
5/CD
years/NNS
after/IN
birth/DT
./.
====================
The/DT
dead/JJ
case/NN
also/RB
happened/VBD
to/TO
a/DT
very/RB
high-risk/JJ
patient/NN
who/WP
was/VBD
unlikely/RB
to/TO
survive/VB
because/IN
of/IN
the/DT
disease/NN
./.
====================
If/IN
the/DT
treatment/NN
was/VBD
started/VBN
after/IN
5/CD
years/NNS
but/CC
within/IN
10/CD
years/NNS
from/IN
birth/DT
,/,
the/DT
survival/NN
rate/NN
is/VBZ
86/CD
%/NN
(/(
3/LS
deaths/NNS
out/IN
of/IN
22/CD
cases/NNS
)/)
,/,
and/CC
if/IN
the/DT
treatment/NN
was/VBD
used/VBN
after/IN
10/CD
years/NNS
from/IN
birth/DT
,/,
the/DT
survival/NN
rate/NN
reduces/VBZ
significantly/RB
to/TO
69/CD
%/NN
(/(
4/CD
deaths/NNS
out/IN
of/IN
13/CD
cases/NNS
)/)
./.
====================
Among/IN
the/DT
very/RB
high-risk/JJ
patients/NNS
ALL123/NN
,/,
ALL143/NN
,/,
ALL144/NN
,/,
and/CC
ALL302/NN
(/(
top-left/NN
)/)
,/,
patient/NN
ALL302/NN
(/(
near/JJ
bottom-right/CC
)/)
was/VBD
the/DT
only/RB
survivor/NN
whose/WP$
genetic/JJ
property/NN
was/VBD
significantly/RB
different/JJ
from/IN
the/DT
others/NNS
(/(
at/IN
the/DT
top-left/NN
)/)
./.
====================
Further/RB
examination/NN
using/VBG
the/DT
250/CD
GOIs/NNS
illustrated/JJ
in/IN
Fig/NN
./.
====================
15/CD
confirms/VBZ
this/DT
hypothesis/NN
for/IN
the/DT
expression/NN
values/NNS
,/,
especially/RB
for/IN
the/DT
genes/NNS
ABHD10/CD
,/,
LEPREL1/NN
,/,
CNOT4/NN
,/,
CHD9/NN
,/,
EPOR/NN
,/,
RASAL2/NN
,/,
ZNF141/NN
,/,
and/CC
SLC25A31/NN
./.
====================
The/DT
variation/NN
at/IN
a/DT
particular/JJ
gene/NN
or/CC
a/DT
combination/NN
of/IN
these/DT
genes/NNS
might/MD
have/VB
contributed/VBN
to/TO
the/DT
survival/NN
rate/NN
or/CC
an/DT
improvement/NN
in/IN
treatment/NN
./.
====================
This/DT
finding/NN
can/MD
be/VB
verified/VBN
by/IN
further/JJ
analysis/NN
using/VBG
larger/JJR
and/CC
more/RBR
comprehensive/JJ
datasets/NNS
and/CC
,/,
ultimately/RB
,/,
the/DT
actual/JJ
proof/NN
of/IN
the/DT
clinical/JJ
experiments/NNS
./.
====================
Patients/NNS
who/WP
were/VBD
born/VBN
in/IN
later/JJ
years/NNS
have/VBP
a/DT
better/RBR
chance/NN
of/IN
survival/NN
./.
====================
For/IN
example/NN
,/,
the/DT
rate/NN
of/IN
survival/NN
for/IN
those/DT
patients/NNS
born/VBD
after/IN
1995/CD
was/VBD
approximately/RB
94/CD
%/NN
while/IN
the/DT
rate/NN
for/IN
those/DT
patients/NNS
born/VBD
before/IN
1995/CD
was/VBD
approximately/RB
83/CD
%/NN
./.
====================
This/DT
property/NN
reflects/VBZ
the/DT
improvement/NN
in/IN
treatment/NN
technology/NN
,/,
treatment/NN
methodology/NN
,/,
and/CC
living/JJ
conditions/NNS
./.
====================
Female/JJ
patients/NNS
tend/VBP
to/TO
fare/VB
better/RBR
than/IN
male/JJ
patients/NNS
overall/JJ
(/(
see/VB
Fig/NN
./.
====================
16/CD
)/)
./.
====================
There/EX
is/VBZ
a/DT
92.5/CD
%/NN
chance/NN
of/IN
survival/NN
in/IN
females/NNS
(/(
3/CD
dead/JJ
cases/NNS
out/RP
of/IN
40/CD
)/)
versus/CC
an/DT
88.3/CD
%/NN
chance/NN
of/IN
survival/NN
in/IN
males/NNS
(/(
7/CD
dead/JJ
cases/NNS
out/RP
of/IN
60/CD
)/)
./.
====================
The/DT
Study/NN
8/CD
protocol/NN
is/VBZ
dominant/JJ
./.
====================
The/DT
BFM/NN
95/CD
protocol/NN
is/VBZ
mostly/RB
applied/VBN
to/TO
standard-/VB
to/TO
medium-risk/VB
patients/NNS
who/WP
were/VBD
born/VBN
before/IN
2000/CD
./.
====================
The/DT
Study/NN
8/CD
protocol/NN
is/VBZ
a/DT
much/RB
more/RBR
popular/JJ
method/NN
,/,
and/CC
it/PRP
was/VBD
used/VBN
for/IN
patients/NNS
regardless/RB
of/IN
risk/NN
strategies/NNS
and/CC
age/NN
./.
====================
Fig/NN
./.
====================
17/CD
shows/VBZ
the/DT
protocols/NNS
used/VBN
in/IN
ALL/NN
treatment/NN
,/,
including/VBG
Study/NN
8/CD
(/(
green/CD
)/)
,/,
BFM/NN
95/CD
(/(
blue/JJ
)/)
,/,
Interfant/JJ
99/CD
(/(
orange/NN
)/)
,/,
and/CC
others/NNS
(/(
red/JJ
)/)
./.
====================
Chemotherapy/NN
is/VBZ
more/RBR
effective/JJ
in/IN
treatment/NN
./.
====================
It/PRP
is/VBZ
interesting/JJ
that/IN
nearly/RB
one-half/JJ
of/IN
all/DT
patients/NNS
did/VBD
not/RB
have/VB
any/DT
treatments/NNS
(/(
or/CC
there/EX
were/VBD
no/DT
treatment/NN
records/VBZ
)/)
on/IN
record/NN
./.
====================
The/DT
untreated/JJ
patients/NNS
mostly/RB
have/VBP
standard/JJ
to/TO
MRs/NNS
./.
====================
The/DT
bone/NN
marrow/NN
transplant/JJ
treatment/NN
method/NN
has/VBZ
little/JJ
effect/NN
on/IN
the/DT
survival/NN
rate/NN
(/(
only/RB
1/CD
out/IN
of/IN
5/CD
cases/NNS
survived/VBD
)/)
./.
====================
The/DT
most/JJS
commonly/RB
chosen/NN
treatment/NN
method/NN
is/VBZ
chemotherapy/NN
,/,
the/DT
survival/NN
rate/NN
for/IN
which/WDT
is/VBZ
over/IN
90/CD
%/NN
(/(
see/VB
Fig/NN
./.
====================
18/CD
)/)
./.
====================
The/DT
visual/JJ
analysis/NN
loop/NN
./.
====================
Visual/JJ
analytics/NNS
model/NN
,/,
reflecting/VBG
the/DT
engagement/NN
of/IN
the/DT
domain/NN
knowledge/NN
in/IN
the/DT
visual/JJ
analytics/NNS
process/NN
./.
====================
GOI/NN
,/,
genes/NNS
of/IN
interest/NN
./.
====================
2D/CD
visualization/NN
of/IN
the/DT
entire/JJ
patient/NN
sample/NN
./.
====================
The/DT
entire/JJ
100/CD
patients/NNS
in/IN
the/DT
2D/JJ
similarity/NN
space/RB
with/IN
mapping/VBG
attributes/VBZ
of/IN
1/CD
)/)
color/JJ
→/NNP
risk/NN
stratification/JJ
(/(
red/JJ
,/,
very/RB
high/JJ
risk/NN
;/:
orange/RB
,/,
high/JJ
risk/NN
;/:
blue/JJ
,/,
medium/NN
risk/NN
;/:
green/RB
,/,
normal/JJ
;/:
and/CC
purple/JJ
,/,
unknown/JJ
)/)
,/,
2/CD
)/)
shape/VBP
→/NNP
gender/IN
(/(
O/NNP
,/,
female/JJ
;/:
X/NN
,/,
male/JJ
)/)
,/,
and/CC
3/CD
)/)
bar/JJ
→/NNP
status/NN
(/(
top-bar/JJ
,/,
deceived/VBD
;/:
no-bar/RB
,/,
survived/VBD
)/)
./.
====================
It/PRP
shows/VBZ
that/IN
most/JJS
of/IN
the/DT
deceased/VBN
patients/NNS
are/VBP
located/JJ
in/IN
the/DT
top-left/NN
area/NN
./.
====================
3D/NN
visualization/NN
of/IN
the/DT
entire/JJ
patient/NN
sample/NN
./.
====================
The/DT
entire/JJ
100/CD
patients/NNS
using/VBG
the/DT
orange-purple/JJ
color-blind/VBP
friendly/RB
scheme/NN
using/VBG
the/DT
same/JJ
dataset/NN
as/IN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
1/CD
)/)
Main/JJ
colors/NNS
(/(
spheres/NNS
)/)
represent/VBP
year/NN
of/IN
birth/DT
,/,
2/CD
)/)
outer/RB
colors/NNS
(/(
signs/NNS
)/)
represent/VBP
risk/NN
stratifications/NNS
(/(
red/JJ
,/,
very/RB
high/JJ
risk/NN
;/:
orange/RB
,/,
high/JJ
risk/NN
;/:
yellow/RB
,/,
medium/NN
risk/NN
;/:
green/RB
,/,
normal/JJ
;/:
and/CC
grey/RB
,/,
unknown/JJ
)/)
,/,
and/CC
3/CD
)/)
status/NN
(/(
bright/JJ
outer-bound/IN
,/,
deceived/VBD
;/:
no-out-bound/RB
,/,
survived/VBD
)/)
./.
====================
Visualization/NN
at/IN
an/DT
exploration/NN
stage/NN
./.
====================
Patients/NNS
with/IN
medium/NN
risk/NN
who/WP
were/VBD
treated/VBN
with/IN
the/DT
Study/NN
8/CD
and/CC
BFM/NN
95/CD
protocols/NNS
./.
====================
Visualization/NN
showing/VBG
the/DT
mapping/NN
by/IN
a/DT
probset/NN
./.
====================
Probeset/NN
``/CD
212022_s_at/JJ
''/CD
is/VBZ
applied/VBN
to/TO
specify/VB
the/DT
colors/NNS
across/IN
the/DT
population/NN
;/:
green/VBN
color/JJ
corresponds/VBZ
to/TO
high/JJ
values/NNS
and/CC
red/JJ
color/JJ
corresponds/VBZ
to/TO
low/JJ
values/NNS
./.
====================
It/PRP
indicates/VBZ
clearly/RB
the/DT
significant/JJ
difference/NN
of/IN
patients/NNS
in/IN
the/DT
bottom-left/JJ
cluster/NN
,/,
who/WP
are/VBP
mostly/RB
painted/JJ
with/IN
``/NN
greenish/VBP
''/CD
colors/NNS
corresponding/VBG
to/TO
the/DT
high/JJ
values/NNS
,/,
in/IN
comparison/NN
to/TO
reddish/VB
colors/NNS
corresponding/VBG
to/TO
the/DT
low/JJ
values/NNS
./.
====================
Visualization/NN
with/IN
clustering/NN
./.
====================
Four/CD
groups/NNS
of/IN
patients/NNS
in/IN
the/DT
cohort/NN
corresponding/VBG
to/TO
four/CD
colors/NNS
(/(
red/JJ
,/,
orange/NN
,/,
green/VBN
,/,
and/CC
blue/JJ
)/)
./.
====================
The/DT
first/JJ
group/NN
(/(
red/JJ
color/NN
)/)
contains/VBZ
mostly/RB
deceased/VBD
patients/NNS
(/(
with/IN
a/DT
bar/JJ
on/IN
top/NN
)/)
./.
====================
Detailed/JJ
view/NN
of/IN
the/DT
genomic/JJ
and/CC
biological/JJ
data/NNS
of/IN
a/DT
patient/NN
./.
====================
Detailed/JJ
view/NN
for/IN
patient/NN
ALL323/NN
./.
====================
The/DT
top-left/NN
panel/NN
displays/VBZ
information/NN
of/IN
the/DT
Affymetrix/JJ
expression/NN
microarrays/NNS
;/:
the/DT
top-right/NN
panel/NN
displays/VBZ
information/NN
of/IN
the/DT
Illumina/NN
SNPs/NNS
;/:
the/DT
middle/JJ
table/JJ
displays/VBZ
all/DT
background/NN
information/NN
of/IN
the/DT
patient/NN
;/:
and/CC
the/DT
bottom/CC
table/JJ
displays/VBZ
the/DT
treatment/NN
details/VBZ
./.
====================
The/DT
view/NN
also/RB
highlights/VBZ
the/DT
pattern/NN
of/IN
the/DT
gene/NN
expression/NN
data/NNS
and/CC
a/DT
gap/JJ
in/IN
the/DT
single/JJ
nucleotide/NN
polymorphism/NN
data/NNS
./.
====================
Visualization/NN
of/IN
a/DT
patient/NN
at/IN
various/JJ
navigational/JJ
stages/NNS
and/CC
options/NNS
./.
====================
Views/RB
of/IN
patient/NN
ALL323/NNP
when/WRB
the/DT
genes/NNS
of/IN
interest/JJ
are/VBP
emphasized/VBN
from/IN
the/DT
structure/NN
(/(
A/DT
)/)
,/,
the/DT
view/NN
shows/VBZ
the/DT
genes/NNS
of/IN
interest/JJ
only/RB
(/(
B/NN
)/)
,/,
the/DT
significantly/RB
different/JJ
genes/NNS
are/VBP
highlighted/JJ
(/(
C/NN
)/)
,/,
the/DT
significantly/RB
different/JJ
genes/NNS
are/VBP
highlighted/JJ
within/IN
the/DT
genes/NNS
of/IN
interest/JJ
(/(
D/NN
)/)
,/,
zoom/IN
in/IN
is/VBZ
applied/VBN
to/TO
single-nucleotide/JJ
polymorphism/NN
data/NNS
(/(
at/IN
the/DT
right-panel/JJ
)/)
(/(
E/NNP
)/)
,/,
and/CC
further/RB
zoom/IN
is/VBZ
applied/VBN
to/TO
gene/NN
expression/NN
data/NNS
(/(
at/IN
the/DT
left-panel/NN
)/)
(/(
F/NN
)/)
so/RB
that/IN
detailed/JJ
information/NN
of/IN
the/DT
probe/NN
sets/NNS
in/IN
genes/NNS
is/VBZ
displayed/VBN
./.
====================
Comparison/NN
windows/VBZ
for/IN
patients/NNS
./.
====================
Comparison/NN
windows/VBZ
for/IN
three/CD
patients/NNS
,/,
namely/RB
ALL323/NN
,/,
ALL48/NN
,/,
and/CC
ALL134/NN
,/,
respectively/RB
./.
====================
The/DT
difference/NN
is/VBZ
highlighted/VBN
in/IN
the/DT
yellow/NN
boxes/NNS
in/IN
the/DT
single/JJ
nucleotide/NN
polymorphism/NN
panel/NN
and/CC
the/DT
corresponding/JJ
enlarged/JJ
red/JJ
boxes/NNS
./.
====================
Genes/NNS
of/IN
interests/NNS
visual/JJ
analysis/NN
for/IN
patients/NNS
./.
====================
There/EX
are/VBP
5/CD
separate/JJ
visual/JJ
components/NNS
the/DT
primary/JJ
patient/NN
probeset/NN
heatmap/RB
component/NN
(/(
component/NN
A/DT
)/)
,/,
the/DT
gene/NN
zoom/IN
component/NN
(/(
component/NN
B/NN
)/)
,/,
the/DT
color/JJ
gradient/JJ
and/CC
Gaussian/JJ
curve/JJ
component/NN
(/(
component/NN
C/NN
)/)
,/,
the/DT
gene/NN
ontology/RB
and/CC
probeset/NN
annotation/NN
component/NN
(/(
component/NN
D/NN
)/)
,/,
and/CC
the/DT
patient/NN
biomedical/JJ
data/NNS
component/NN
(/(
component/NN
E/NN
)/)
./.
====================
A/DT
seamless/VBP
analysis/NN
from/IN
overview/NN
to/TO
detailed/JJ
view/NN
to/TO
genes/NNS
of/IN
interest/NN
./.
====================
Transition/NN
view/NN
from/IN
overview/NN
of/IN
three/CD
patients/NNS
(/(
ALL123/NN
,/,
ALL26/NN
,/,
and/CC
ALL302/NN
)/)
in/IN
the/DT
similarity/NN
space/NN
(/(
A/DT
)/)
to/TO
patient-to-patient/JJ
comparison/NN
view/NN
(/(
B/NN
)/)
and/CC
finally/RB
to/TO
the/DT
genes/NNS
of/IN
interest/NN
view/NN
(/(
C/NN
)/)
./.
====================
Genetic/JJ
variation/NN
in/IN
the/DT
clusters/NNS
of/IN
patients/NNS
./.
====================
All/DT
probe/NN
sets/NNS
in/IN
gene/NN
MKI67/NN
(/(
highlighted/JJ
)/)
in/IN
group/NN
0/CD
(/(
or/CC
cluster/NN
0/CD
)/)
are/VBP
significantly/RB
different/JJ
from/IN
the/DT
other/JJ
groups/NNS
./.
====================
Genetic/JJ
variation/NN
in/IN
patients/NNS
despite/IN
the/DT
similarity/NN
in/IN
biomedical/JJ
data/NNS
./.
====================
Details/NNS
of/IN
several/JJ
genes/NNS
of/IN
interest/NN
for/IN
the/DT
four/CD
patients/NNS
:/:
ALL92/NN
,/,
ALL129/NN
,/,
ALL321/NN
,/,
and/CC
ALL323/NN
./.
====================
The/DT
patients/NNS
'/``
clinical/JJ
properties/NNS
are/VBP
similar/JJ
,/,
including/VBG
medium/NN
risk/NN
,/,
male/JJ
,/,
deceased/VBD
,/,
and/CC
Study/NN
8/CD
protocol/NN
./.
====================
However/RB
,/,
the/DT
Affymetrix/JJ
expression/NN
microarrays/NNS
and/CC
Illumina/NN
SNP/NN
values/NNS
are/VBP
quite/RB
varied/VBN
among/IN
these/DT
patients/NNS
./.
====================
The/DT
survival/NN
rate/NN
by/IN
year/NN
of/IN
treatment/NN
:/:
treatment/NN
within/IN
5/CD
years/NNS
from/IN
birth/DT
(/(
A/DT
)/)
,/,
treatment/NN
after/IN
within/IN
5/CD
to/TO
10/CD
years/NNS
from/IN
birth/DT
(/(
B/NN
)/)
,/,
and/CC
treatment/NN
after/IN
10/CD
years/NNS
from/IN
birth/DT
(/(
C/NN
)/)
,/,
respectively/RB
./.
====================
Early/JJ
treatments/NNS
are/VBP
more/RBR
effective/JJ
than/IN
late/JJ
treatments/NNS
./.
====================
The/DT
genetic/JJ
property/NN
of/IN
high-risk/JJ
patients/NNS
./.
====================
For/IN
the/DT
very/RB
high-risk/JJ
patients/NNS
,/,
the/DT
genetic/JJ
property/NN
of/IN
patient/NN
ALL302/NN
(/(
the/DT
only/RB
survivor/NN
at/IN
the/DT
bottom-right/JJ
)/)
is/VBZ
significantly/RB
different/JJ
from/IN
the/DT
others/NNS
(/(
at/IN
the/DT
top-left/NN
)/)
./.
====================
Further/RB
examination/NN
using/VBG
the/DT
250/CD
genes/NNS
of/IN
interest/NN
confirms/VBZ
this/DT
hypothesis/NN
for/IN
the/DT
expression/NN
values/NNS
,/,
especially/RB
for/IN
the/DT
genes/NNS
ABHD10/CD
,/,
LEPREL1/NN
,/,
CNOT4/NN
,/,
CHD9/NN
,/,
EPOR/NN
,/,
RASAL2/NN
,/,
ZNF141/NN
,/,
and/CC
SLC25A31/NN
./.
====================
Views/NNS
of/IN
patients/NNS
who/WP
are/VBP
females/NNS
(/(
A/NN
)/)
and/CC
males/NNS
(/(
B/NN
)/)
,/,
respectively/RB
./.
====================
Female/JJ
patients/NNS
tend/VBP
to/TO
fare/VB
better/RBR
than/IN
male/JJ
patients/NNS
overall/JJ
./.
====================
Views/NNS
of/IN
patients/NNS
with/IN
different/JJ
protocols/NNS
,/,
including/VBG
Study/NN
8/CD
,/,
BFM/NN
95/CD
,/,
Interfant/JJ
99/CD
,/,
and/CC
others/NNS
./.
====================
The/DT
larger/JJR
items/VBZ
represent/JJ
deceased/VBD
patients/NNS
,/,
and/CC
the/DT
colors/NNS
represent/JJ
the/DT
protocols/NNS
,/,
including/VBG
Study/NN
8/CD
(/(
green/CD
)/)
,/,
BFM/NN
95/CD
(/(
blue/JJ
)/)
,/,
Interfant/JJ
99/CD
(/(
orange/NN
)/)
,/,
and/CC
others/NNS
(/(
red/JJ
)/)
./.
====================
Views/NNS
of/IN
patients/NNS
with/IN
different/JJ
treatment/NN
protocols/NNS
,/,
including/VBG
chemotherapy/NN
and/CC
bone/NN
marrow/NN
transplant/JJ
./.
====================
Chemotherapy/NN
is/VBZ
more/RBR
effective/JJ
in/IN
treatment/NN
(/(
green/CD
color/JJ
)/)
./.
====================
It/PRP
is/VBZ
interesting/JJ
that/IN
nearly/RB
one-half/NN
of/IN
all/DT
patients/NNS
did/VBD
not/RB
have/VB
any/DT
treatments/NNS
(/(
blue/JJ
color/JJ
)/)
./.
====================
The/DT
untreated/JJ
patients/NNS
mostly/RB
had/VBD
standard/JJ
to/TO
medium/NN
risks/NNS
./.
====================
